Ovarian Cancers Advances through International Research Cooperation (GINECO, ENGOT, GCIG) /

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surg...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Pujade-Lauraine, Eric (Επιμελητής έκδοσης), Ray-Coquard, Isabelle (Επιμελητής έκδοσης), Lécuru, Fabrice (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2017.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • Ovarian cancer management
  • Clinical research in Europe dedicated to ovarian cancers
  • Oncogenetics
  • Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality
  • How to evaluate tumor burden before therapeutic decision
  • Value of lymphadenectomy
  • HYPEC: what is the evidence?
  • Onco-fertility applied to ovarian cancers
  • First-line systemic therapy (chemo/antiangiogenics)
  • Elderly
  • Treatment at relapse (surgery & systemic treatments)
  • How to evaluate QoL
  • The future in ovarian cancers & place of the new immunotherapies in ovarian cancers
  • Particular types of ovarian cancers
  • High grade serous carcinoma & BRCA mutation anti-PARP
  • Borderline and low grade carcinoma
  • Clear Cell carcinoma
  • Endometrioid carcinoma
  • Mucinous carcinoma
  • Carcinosarcoma
  • Germ cell tumors
  • Sex cord tumors
  • Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management
  • Clinical research in Europe dedicated to ovarian cancers
  • Oncogenetics
  • Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality
  • How to evaluate tumor burden before therapeutic decision
  • Value of lymphadenectomy
  • HYPEC: what is the evidence?
  • Onco-fertility applied to ovarian cancers
  • First-line systemic therapy (chemo/antiangiogenics)
  • Elderly
  • Treatment at relapse (surgery & systemic treatments)
  • How to evaluate QoL
  • The future in ovarian cancers & place of the new immunotherapies in ovarian cancers
  • Particular types of ovarian cancers
  • High grade serous carcinoma & BRCA mutation anti-PARP
  • Borderline and low grade carcinoma
  • Clear Cell carcinoma
  • Endometrioid carcinoma
  • Mucinous carcinoma
  • Carcinosarcoma
  • Germ cell tumors
  • Sex cord tumors
  • Very rare ovarian malignant tumors including small cell carcinoma.